A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells

Retrovirology

Volumn 8, Issue , 2011, Pages

  Melchers, Mark ^a   Matthews, Katie ^b   de Vries, Robert P ^a   Eggink, Dirk ^a   van Montfort, Thijs ^a   Bontjer, Ilja ^a   van de Sandt, Carolien ^a   David, Kathryn ^b   Berkhout, Ben ^a   Moore, John P ^b   Sanders, Rogier W ^a,b  

^a Department of Medical Microbiology Center for Infection and Immunity Amsterdam ^*  (Netherlands)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; GLYCOPROTEIN GP 140 CD40 LIGAND FUSION PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; CD40 LIGAND; CYTOKINE;

ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DESIGN; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; CELL CULTURE; CELL DIFFERENTIATION; CHEMISTRY; GENETICS; IMMUNOLOGY; METABOLISM; PROTEIN STABILITY; SECRETION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CD40 LIGAND; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; PROTEIN STABILITY; RECOMBINANT FUSION PROTEINS;

EID: 79959217462     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-48     Document Type: Article

References (64)

1. Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, Weinfurter JT, Kaizu M, Soma T, Leon EJ, MacNair C, Leaman DP, Zwick MB, Gostick E, Musani SK, Price DA, Friedrich TC, Rakasz EG, Wilson NA, McDermott AB, Boyle R, Allison DB, Burton DR, Koff WC, Watkins DI. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 2008, 205:2537-2550. 10.1084/jem.20081524, 2571929, 18838548.
2. Liu J, O'Brien KL, Lynch DM, Simmons NL, La PA, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87-91. 10.1038/nature07469, 2614452, 18997770.
3. Shattock RJ, Haynes BF, Pulendran B, Flores J, Esparza J. Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 2008, 5:e81. 10.1371/journal.pmed.0050081, 2276525, 18384232.
4. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
5. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van GF, Hu D, Tappero JW, Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671. 10.1086/508748, 17109337.
6. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5:233-236. 10.1038/ni0304-233, 14985706.
7. Eggink D, Melchers M, Sanders RW. Antibodies to HIV-1: aiming at the right target. Trends Microbiol 2007, 15:291-294. 10.1016/j.tim.2007.05.006, 17566740.
8. Kwong PD, Wilson IA. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 2009, 10:573-578. 10.1038/ni.1746, 2796958, 19448659.
9. Parren PW, Burton DR, Sattentau QJ. HIV-1 antibody--debris or virion?. Nat Med 1997, 3:366-367.
10. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010, 22(3):358-66. Epub 2010 Mar 17, 10.1016/j.coi.2010.02.012, 2891291, 20299194.
11. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, Kajumo F, Anselma DJ, Maddon PJ, Olson WC, Moore JP. A recombinant HIV-1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000, 74:627-643. 10.1128/JVI.74.2.627-643.2000, 111582, 10623724.
12. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002, 76:8875-8889. 10.1128/JVI.76.17.8875-8889.2002, 136973, 12163607.
13. Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001, 75:1165-1171. 10.1128/JVI.75.3.1165-1171.2001, 114022, 11152489.
14. Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, Hilt S, Martin L, Vita C, Zhu P, Roux KH, Vojtech L, C Montefiori D, Donnelly J, Ulmer JB, Barnett SW. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003, 77:11244-11259. 10.1128/JVI.77.20.11244-11259.2003, 224963, 14512572.
15. Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ Maddon PJ, Olson WC, Moore JP. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virol 2007, 360:329-340.
16. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in aphase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005, 191:666-677. 10.1086/428405, 15688279.
17. Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, Hicks CB, Vandergrift N, Tomaras GD, Haynes BF. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol 2009, 183:2708-2717. 10.4049/jimmunol.0901068, 3089979, 19625640.
18. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009, 15:34-41. 10.1038/nm.1894, 2987729, 19079256.
19. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005, 102:15190-15194. 10.1073/pnas.0507484102, 1257732, 16219698.
20. Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood 2009, 113:3969-3977. 10.1182/blood-2008-10-185421, 19144984.
21. Bower JF, Yang X, Sodroski J, Ross TM. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 2004, 78:4710-4719. 10.1128/JVI.78.9.4710-4719.2004, 387675, 15078953.
22. Koch M, Frazier J, Sodroski J, Wyatt R. Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d. Virol 2005, 340:277-284.
23. McCormick AL, Thomas MS, Heath AW. Immunization with an interferon-gamma-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120. J Inf Dis 2001, 184:1423-1430.
24. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199:815-824. 10.1084/jem.20032220, 2212731, 15024047.
25. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, Steinman RM, Nussenzweig MC. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315:107-111. 10.1126/science.1136080, 17204652.
26. Yang L, Yang H, Rideout K, Cho T, Joo KI, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D, Wang P. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008, 26:326-334. 10.1038/nbt1390, 2366162, 18297056.
27. Lahoud MH, Proietto AI, Ahmet F, Kitsoulis S, Eidsmo L, Wu L, Sathe P, Pietersz S, Chang HW, Walker ID, Maraskovsky E, Braley H, Lew AM, Wright MD, Heath WR, Shortman K, Caminschi I. The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol 2009, 182:7587-7594. 10.4049/jimmunol.0900464, 19494282.
28. Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 2009, 21:265-272. 10.1016/j.smim.2009.05.010, 2749083, 19524453.
29. Caux C, Massacrier C, Vanbervliet B, Dubois B, van KC, Durand I, Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994, 180:1263-1272. 10.1084/jem.180.4.1263, 2191669, 7523569.
30. S hreedhar V, Moodycliffe AM, Ullrich SE, Bucana C, Kripke ML, Flores-Romo L. Dendritic cells require T cells for functional maturation in vivo. Immunity 1999, 11:625-636. 10.1016/S1074-7613(00)80137-5, 10591187.
31. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000, 67:2-17.
32. Gray D, Siepmann K, Wohlleben G. CD40 ligation in B cell activation, isotype switching and memory development. Semin Immunol 1994, 6:303-310. 10.1006/smim.1994.1039, 7532460.
33. Mendoza RB, Cantwell MJ, Kipps TJ. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol 1997, 159:5777-5781.
34. Dullforce P, Sutton DC, Heath AW. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nat Med 1998, 4:88-91. 10.1038/nm0198-088, 9427612.
35. Gurunathan S, Irvine KR, Wu CY, Cohen JI, Thomas E, Prussin C, Restifo NP, Seder RA. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol 1998, 161:4563-4571. 2239005, 9794383.
36. Rolph MS, Kaufmann SH. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes. J Immunol 2001, 166:5115-5121.
37. Ninomiya A, Ogasawara K, Kajino K, Takada A, Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 2002, 20:3123-3129. 10.1016/S0264-410X(02)00261-X, 12163263.
38. Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP, Tevethia SS. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol 2003, 171:697-707.
39. Wienhold D, Armengol E, Marquardt A, Marquardt C, Voigt H, Buttner M, Saalmuller A, Pfaff E. Immunomodulatory effect of plasmids co-expressing cytokines in classical swine fever virus subunit gp55/E2-DNA vaccination. Vet Res 2005, 36:571-587. 10.1051/vetres:2005019, 15955282.
40. Llopiz D, Dotor J, Zabaleta A, Lasarte JJ, Prieto J, Borras-Cuesta F, Sarobe P. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunol Immunother 2008, 57:19-29. 10.1007/s00262-007-0346-8, 17564702.
41. Zhang R, Zhang S, Li M, Chen C, Yao Q. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine 2010, 28(31):5114-27. Epub 2010 May 14, 10.1016/j.vaccine.2010.03.079, 20471443.
42. Skountzou I, Quan FS, Gangadhara S, Ye L, Vzorov A, Selvaraj P, Jacob J, Compans RW, Kang SM. Incorporation of glycosylphosphatidylinositol-anchored granulocyte-macrophage colonystimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol 2007, 81:1083-1094. 10.1128/JVI.01692-06, 1797543, 17108046.
43. Liu J, Yu Q, Stone GW, Yue FY, Ngai N, Jones RB, Kornbluth RS, Ostrowski MA. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 2008, 26:4062-4072. 10.1016/j.vaccine.2008.05.018, 3060027, 18562053.
44. Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Ghalie R, Caron DA, Gribben JG. Phase I study of recombinant human CD40 ligand in cancer patients. Journal of Clinical Oncology 2001, 19:3280-3287.
45. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, Travis B, Kuhmann S, Burton DR, Hu S-L, Olsos WC, Moore JP. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2002, 76:2606-2616. 10.1128/JVI.76.6.2606-2616.2002, 135977, 11861826.
46. Harbury PB, Kim PS, Alber T. Crystal structure of an isoleucine-zipper trimer. Nature 1994, 371:80-83. 10.1038/371080a0, 8072533.
47. Eggink D, Melchers M, Wuhrer M, van MT, Dey AK, Naaijkens BA, David KB, Le D, Deelder AM, Kang K, Olson WC, Berkhout B, Hokke CH, Moore JP, Sanders RW. Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virol 2010, 401:236-247.
48. Kirschner M, Monrose V, Paluch M, Techodamrongsin N, Rethwilm A, Moore JP. The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr Purif 2006, 48:61-68. 10.1016/j.pep.2006.02.017, 16600625.
49. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187. 10.1038/384184a0, 8906796.
50. Schagger H, Cramer WA, von JG. Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis. Anal Biochem 1994, 217:220-230. 10.1006/abio.1994.1112, 8203750.
51. Schagger H, von JG. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal Biochem 1991, 199:223-231. 10.1016/0003-2697(91)90094-A, 1812789.
52. Yang X, Florin L, Farzan M, Kolchinsky P, Kwong PD, Sodroski J, Wyatt R. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol 2000, 74:4746-4754. 10.1128/JVI.74.10.4746-4754.2000, 111997, 10775613.
53. Pancera M, Lebowitz J, Schon A, Zhu P, Freire E, Kwong PD, Roux KH, Sodroski J, Wyatt R. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J Virol 2005, 79:9954-9969. 10.1128/JVI.79.15.9954-9969.2005, 1181572, 16014956.
54. Si Z, Phan N, Kiprilov E, Sodroski J. Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res Hum Retroviruses 2003, 19:217-226. 10.1089/088922203763315722, 12689414.
55. Morris AE, Remmele RL, Klinke R, Macduff BM, Fanslow WC, Armitage RJ. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem 1999, 274:418-423. 10.1074/jbc.274.1.418, 9867859.
56. Stone GW, Barzee S, Snarsky V, Spina CA, Lifson JD, Pillai VK, Amara RR, Villinger F, Kornbluth RS. Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clin Vaccine Immunol 2006, 13:1223-1230. 10.1128/CVI.00198-06, 1656546, 16988005.
57. Haswell LE, Glennie MJ, Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 2001, 31:3094-3100. 10.1002/1521-4141(2001010)31:10<3094::AID-IMMU3094>3.0.CO;2-F, 11592086.
58. Maurais E, Cantin R, Tremblay MJ. Human immunodeficiency virus type 1-anchored CD40 ligand induces secretion of the chemokine interleukin-8 by human primary macrophages. Virol 2009, 385:227-232.
59. Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SP, Dionisio R, Charles D, Campbell-Gardener L, Olson WC, Sanders RW, Moore JP. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog 2007, 3:e169. 10.1371/journal.ppat.0030169, 2048530, 17983270.
60. Li W. Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen. Immunology 2005, 115:215-222. 10.1111/j.1365-2567.2005.02141.x, 1782153, 15885127.
61. Chen HW, Huang HI, Lee YP, Chen LL, Liu HK, Cheng ML, Tsai JP, Tao MH, Ting CC. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cellbased treatment. Cancer Immunol Immunother 2002, 51:341-348. 10.1007/s00262-002-0283-5, 12111122.
62. Huang HI, Wu PY, Teo CY, Chen MN, Chen YC, Silin D, Tao MH. Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand. International Journal of Cancer 2004, 108:696-703.
63. Manoj S, Griebel PJ, Babiuk LA, Littel-Van Den Hurk SV. Modulation of immune responses to bovine herpesvirus-1 in cattle by immunization with a DNA vaccine encoding glycoprotein D as a fusion protein with bovine CD154. Immunology 2004, 112:328-338. 10.1111/j.1365-2567.2004.01877.x, 1782479, 15147576.
64. Gares SL, Fischer KP, Congly SE, Lacoste S, Addison WR, Tyrrell DL, Gutfreund KS. Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks. Clin Vaccine Immunol 2006, 13:958-965. 10.1128/CVI.00080-06, 1539120, 16893998.